Pfizer, Teva settle lawsuits
Pfizer and generic drug giant Teva Pharmaceuticals have come to an agreement over three drugs, ending two lawsuits over Pfizer's cancer drug Idamycin and antibiotic Zithromax. "Under the settlement, Teva will pay Pfizer $70 million and agrees not to contest the validity of the respective drug's patents. Teva will be able to continue selling its generic version of Idamycin and Zithromax." Teva also gains the right to manufacture and market a generic version of another Pfizer cancer drug, Ellence.
- read this Ynetnews article for
more on the settlement
- check out Teva's press release on the
agreement
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
